Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+

NCT01220076 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT01220076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01220076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
October 31, 2016
Enrollment
140 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non metastatic breast cancer